A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo

被引：0
作者：
J K J Diss
D Stewart
F Pani
C S Foster
M M Walker
A Patel
M B A Djamgoz
机构：
[1] Neuroscience Solutions to Cancer Research Group,Department of Biological Sciences
[2] Imperial College London,Department of Cellular and Molecular Pathology
[3] South Kensington Campus,Department of Histopathology
[4] Medical Molecular Biology Unit,Department of Urology
[5] Institute of Child Health,undefined
[6] University College London,undefined
[7] Duncan Building,undefined
[8] University of Liverpool,undefined
[9] Imperial College School of Medicine,undefined
[10] St Mary's Hospital,undefined
[11] St Mary's Hospital at Imperial College School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2005年 / 8卷
关键词：
Na; 1.7; immunohistochemistry; real-time PCR; receiver-operating characteristics curve; diagnosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Functional expression of voltage-gated sodium channel α-subunits (VGSCαs), specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSCα expression in CaP in vivo, immunohistochemistry and real-time PCR were performed on human prostate biopsies (n>20). VGSCα immunostaining was evident in prostatic tissues and markedly stronger in CaP vs non-CaP patients. Importantly, RT-PCRs identified Nav1.7 as the VGSCα most strikingly upregulated (∼20-fold) in CaP, and the resultant receiver-operating characteristics curve demonstrated high diagnostic efficacy for the disease. It is concluded that VGSCα expression increases significantly in CaP in vivo and that Nav1.7 is a potential functional diagnostic marker.
引用
收藏
页码：266 / 273
页数：7
相关论文
共 85 条
[1]  
Foster CS(1999)The cellular and molecular basis of prostate cancer Br J Urol Int 83 171-194
[2]  
Graves HC(1995)Nonprostatic sources of prostate-specific antigen: a steroid hormone-dependent phenomenon? Clin Chem 41 7-9
[3]  
Smith MR(1995)Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases Cancer Res 55 2640-2644
[4]  
Biggar S(2001)Prostate-specific antigen best practice policy—Part I: early detection and diagnosis of prostate cancer Urology 57 217-224
[5]  
Hussain M(2001)Prostate-specific antigen best practice policy—Part II: prostate cancer staging and post-treatment follow-up Urology 57 225-229
[6]  
Carroll P(2004)Screening without evidence of efficacy BMJ 328 301-302
[7]  
Carroll P(2002)DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2695-2698
[8]  
Law M(2003)Molecular and genetic prognostic factors of prostate cancer World J Urol 21 265-274
[9]  
de Kok JB(2002)The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 624-629
[10]  
Chakravarti A(1995)Differential expression of voltage-activated Na FEBS Lett 369 290-294
123456789